Registry Stop Signal

Bortezomib

Bortezomib is flagged as registry stop signal because public records show a registry stop signal, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.

Program overview

Context

Indication: Amyloidosis

Mechanism: Unknown

Modality: Unknown

Sponsor: Mayo Clinic

Scores

Risk-signal summary

Registry: 5/5

Timeline: 1/5

Recruitment burden: 2/5

Results availability: 0/5

Program risk: 4/5

Evidence

Public links

https://clinicaltrials.gov/study/NCT03130348 | https://clinicaltrials.gov/study/NCT00792142 | https://clinicaltrials.gov/study/NCT00075881

Linked trials

Trial-level signal details

TrialStatusTimelineResultsBurden
NCT03130348Registry Stop Signal (WITHDRAWN)stale_update_signalLow Signalrare_population_signal | strict_eligibility_signal
NCT00792142Low Signal (COMPLETED)stale_update_signalLow Signalstrict_eligibility_signal
NCT00075881Low Signal (COMPLETED)stale_update_signalLow Signalrare_population_signal | strict_eligibility_signal